More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$5.11B
EPS
-1.2
P/E ratio
--
Price to sales
5.44
Dividend yield
8.987%
Beta
0.378683
Previous close
$56.37
Today's open
$56.49
Day's range
$54.80 - $57.21
52 week range
$22.31 - $93.61
show more
CEO
Roger A. Jeffs
Employees
216
Headquarters
Morrisville, NC
Exchange
NASDAQ Capital Market
Shares outstanding
90106442
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Liquidia: Yutrepia's PAH Franchise Has Room To Grow
Liquidia kept the right to market YUTREPIA for PAH after the settlement with United Therapeutics. This settlement limits YUTREPIA's potential in PH-ILD, but since it can still be sold to patients using it and to patients with PAH, Liquidia Corporation can continue generating revenue. YUTREPIA is already generating cash. Paid PAH starts will show how much of the lost PH-ILD growth LQDA can replace.
Seeking Alpha • Nov 14, 2026

LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
Liquidia reports surging YUTREPIA sales, record October shipments and expanding PAH adoption amid post-settlement market changes and referral disruptions.
Zacks Investment Research • Nov 11, 2026

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
Liquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth.
Zacks Investment Research • Nov 11, 2026

Liquidia Q3 Earnings Call Highlights
Liquidia NASDAQ: LQDA reported a 31% sequential increase in third-quarter YUTREPIA sales as the company sought to reassure investors that its pulmonary arterial hypertension business can continue growing following a patent settlement with United Therapeutics.
MarketBeat • Nov 10, 2026

Liquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript
Liquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 10, 2026

Liquidia Corporation Reports Third Quarter 2026 Financial Results
MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the third quarter ended September 30, 2026. The company will also host a webcast at 8:30 a.m. ET on November 10, 2026, to discuss its financial results and provide a corporate update.
GlobeNewsWire • Nov 10, 2026

Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates
Liquidia Corporation (LQDA) came out with quarterly earnings of $0.8 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to a loss of $0.04 per share a year ago.
Zacks Investment Research • Nov 10, 2026

Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company's business in a fireside chat at the 2026 Jefferies Global Healthcare Conference, Tuesday, November 17, at 10 a.m.
GlobeNewsWire • Nov 10, 2026

Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its third quarter 2026 financial results on Tuesday, November 10, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
GlobeNewsWire • Nov 3, 2026

Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
Zacks Investment Research • Oct 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Liquidia Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.